Mandate

Vinge advises Lantmännen in connection with its acquisition of the Vaasan Group

January 15, 2015

Vinge advises Lantmännen Ek För (”Lantmännen”) in connection with its acquisition of the Vaasan Group (”Vaasan”) from Lion Capital. In 2013, Vaasan had net sales of approx. MEUR 415 and in total approx. 2,745 employees. Vaasan is engaged in the baking industry in the Nordic and Baltic regions and is a worldwide supplier of thin crisp and crisp bread. The purchase price is confidential. The transaction is conditional upon approval by the relevant competition authorities.

Vinge’s team consists of responsible partner Christina Kokko, partner Jonas Johansson and associates Sofie Bjärtun and Alex Miler. Associate Malin Malm has advised on IP matters, Matilda Gustafsson and Johan Cederblad have advised on environmental and real property matters, Anders Morén has advised on financing matters and Sara Strandberg has advised on employment law. Partner Marcus Glader and associates Grant McKelvey, Emil Fahlén Godö, Johan Wahlbom and Victoria Grossmann are advising on the competition law aspects of the transaction.

Vinge has also coordinated the work performed by Castrén & Snellman (Finland), Lawin (Estonia, Latvia and Lithuania), Haavind (Norway), Bech-Bruun (Denmark) and Heuking Kühn Lüer Wojtek (Germany).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025